RecruitingPHASE2, PHASE3NCT07086313

A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD

Studying Cap myopathy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Otsuka Pharmaceutical Co., Ltd.
Principal Investigator
Nobuhito Sanada
Otsuka Pharmaceutical Co., Ltd.
Intervention
EB-1020 (Centanafadine) low dose(drug)
Enrollment
315 enrolled
Eligibility
6-17 years · All sexes
Timeline
20252027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07086313 on ClinicalTrials.gov

Other trials for Cap myopathy

Additional recruiting or active studies for the same condition.

See all trials for Cap myopathy

← Back to all trials